Lonza Potelligent CHOK1SV host cell line

Friday, 20 November, 2009 | Supplied by: Lonza Australia Pty Ltd

Potelligent CHOK1SV, a host cell line for manufacturing recombinant antibodies, combines BioWa’s glycosylation Potelligent technology with Lonza’s GS Gene Expression System and CHOK1SV.

The cell line retains the features of a high-productivity cell line (robust, high-yielding, scalable) and the bioprocess platform for CHOK1SV is repeatable in the new cell line.

Antibodies produced by the new cell line: exhibit enhanced antibody dependent cellular cytotoxicity (ADCC) even with the low-ADCC allotype of CD16, overcoming CD16 polymorphism; can exert potent cytotoxic effects when their target antigen is low; work in whole blood; and retain required features of antibodies, such as Protein A binding.

Online: www.lonza.com
Phone: 03 9550 0883
Related Products

AdipoGen Life Sciences tubulin products for neurodegeneration research

AdipoGen Life Sciences offers a broad range of microtubule research solutions. This includes...

SYnAbs monoclonal antibodies

SYnAbs produces innovative monoclonal antibodies against poor immunogenic compounds and complex...

Merck VirusExpress Lentiviral Production Platform

The platform helps to overcome lentiviral production challenges and can reduce process...

  • All content Copyright © 2020 Westwick-Farrow Pty Ltd